What is NAGE's pharmaceuticals segment — G&A?

NAGE (NAGE) reported pharmaceuticals segment — G&A of $0 in Q1 2026.

What does pharmaceuticals segment — G&A mean?

Covers the overhead costs associated with the management and administration of the pharmaceutical segment, including executive salaries, legal, and office expenses. These costs are necessary to support the segment's operations but are not directly tied to production or sales. Monitoring this helps evaluate the segment's operational leverage.

NAGE NAGE Pharmaceuticals segment — G&A

Other segment segments

Analytical Reference Standards and Services segment

$0—

Consumer Products segment

$0—

Ingredients segment

$0—

Similar metrics at other companies

VRTXPharmaceuticals — General and administrative expenses

$180.1M+16.0%

BLCOPharmaceuticals — Selling, general and administrative (Note 4)

$138M-9.8%

BAXPharmaceuticals — Selling, general and administrative expenses

$102M-1.0%

ANABBiopharma Company — General And Administrative Expense

$18.86M+92.1%

ABTEstablished Pharmaceuticals — Selling, general, and administrative

$376M+7.1%

TBRGPatient Care — G&A

$6.25M+12.3%

Other financials

Income statement

See full

Revenue$31.5M+3.3%

Gross profit$20.0M+3.3%

Operating income$1.6M-67.0%

Net income$6.3M+24.8%

EPS (diluted)$0.07+16.7%

Balance sheet

See full

Cash & equivalents$66.5M+19.7%

Total debt$2.6M-26.9%

Total equity$82.3M+48.8%

Total assets$114.3M+40.6%

Cash flow

See full

Operating cash flow-$1.2M-115%

Valuation

See full

Market cap$254.07M-74.9%

Enterprise value$190.09M-79.7%

P/E13.6×-43.5×

P/S2×-6.8×

Profitability

See full

Gross margin64.3%+1.8pp

Operating margin10%-2.2pp

Net margin14.3%+1.2pp

FCF margin-70.4%—

Returns & leverage

See full

Return on equity27.1%-6.4pp

Debt / equity0×0.0×

Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's pharmaceuticals segment — g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NAGE's pharmaceuticals segment — G&A?: NAGE (NAGE) reported pharmaceuticals segment — G&A of $0 in Q1 2026.
What does pharmaceuticals segment — G&A mean?: Covers the overhead costs associated with the management and administration of the pharmaceutical segment, including executive salaries, legal, and office expenses. These costs are necessary to support the segment's operations but are not directly tied to production or sales. Monitoring this helps evaluate the segment's operational leverage.